EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002
Mottet, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis and local treatment with curative intent, Eur Urol, 71, 618, 10.1016/j.eururo.2016.08.003
Oxford Centre for Evidence-Based Medicine – levels of evidence (March 2009). Centre for Evidence-Based Medicine Web site. http://www.cebm.net/index.aspx?o=1025.
Amling, 2001, Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?, J Urol, 165, 1146, 10.1016/S0022-5347(05)66452-X
Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029
Brockman, 2015, Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy, Eur Urol, 67, 1160, 10.1016/j.eururo.2014.09.019
D’Amico, 2004, Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy, J Urol, 172, S42, 10.1097/01.ju.0000141845.99899.12
Trock, 2008, Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy, JAMA, 299, 2760, 10.1001/jama.299.23.2760
Zumsteg, 2015, The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy, Eur Urol, 67, 1009, 10.1016/j.eururo.2014.09.028
Rouviere, 2010, Imaging of prostate cancer local recurrences: why and how?, Eur Radiol, 20, 1254, 10.1007/s00330-009-1647-4
Beresford, 2010, A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence, Clin Oncol (R Coll Radiol), 22, 46, 10.1016/j.clon.2009.10.015
Ceci, 2014, Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial, Eur J Nucl Med Mol Imaging, 41, 2222, 10.1007/s00259-014-2872-x
Treglia, 2014, Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis, Clin Chem Lab Med, 52, 725, 10.1515/cclm-2013-0675
Abd-Alazeez, 2015, Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images, Prostate Cancer Prostatic Dis, 18, 128, 10.1038/pcan.2014.55
Mitchell, 2013, Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment, J Urol, 189, 1308, 10.1016/j.juro.2012.10.069
Rybalov, 2013, Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-choline positron emission tomography in recurrent prostate cancer, World J Urol, 31, 319, 10.1007/s00345-012-0908-z
Pfister, 2014, Early salvage radiotherapy following radical prostatectomy, Eur Urol, 65, 1034, 10.1016/j.eururo.2013.08.013
Wiegel, 2009, Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study, Int J Radiat Oncol Biol Phys, 73, 1009, 10.1016/j.ijrobp.2008.06.1922
Goenka, 2012, Long-term outcomes after high-dose postprostatectomy salvage radiation treatment, Int J Radiat Oncol Biol Phys, 84, 112, 10.1016/j.ijrobp.2011.10.077
Soto, 2012, Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients, Int J Radiat Oncol Biol Phys, 82, 1227, 10.1016/j.ijrobp.2010.08.030
Shipley, 2016, Report of NRG Oncology/RTOG 9601, a phase 3 trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) in patients following radical prostatectomy (RP) with pT2-3pN0 disease and an elevated PSA, Int J Radiat Oncol Biol Phys, 94, 3, 10.1016/j.ijrobp.2015.10.048
Carrie, 2016, Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial, Lancet Oncol, 17, 747, 10.1016/S1470-2045(16)00111-X
Briganti, 2012, Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis, Eur Urol, 62, 472, 10.1016/j.eururo.2012.04.056
Chade, 2012, Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature, Eur Urol, 61, 961, 10.1016/j.eururo.2012.01.022
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), EJC, 45, 228, 10.1016/j.ejca.2008.10.026
Ismail, 2007, Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients, BJU Int, 100, 760, 10.1111/j.1464-410X.2007.07045.x
Pisters, 2009, Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy, J Urol, 182, 517, 10.1016/j.juro.2009.04.006
Ahmad, 2013, Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer, PLoS One, 8, e69243, 10.1371/journal.pone.0069243
Chen, 2013, Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes, Int J Radiat Oncol Biol Phys, 86, 324, 10.1016/j.ijrobp.2013.01.027
Yamada, 2014, A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy, Brachytherapy, 13, 111, 10.1016/j.brachy.2013.11.005
Lee, 2007, Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience, Int J Radiat Oncol Biol Phys, 67, 1106, 10.1016/j.ijrobp.2006.10.012
Burri, 2010, Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer, Int J Radiat Oncol Biol Phys, 77, 1338, 10.1016/j.ijrobp.2009.06.061
Crouzet, 2012, Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes, Radiother Oncol, 105, 198, 10.1016/j.radonc.2012.09.014
Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004
Karnes, 2015, Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography, J Urol, 193, 111, 10.1016/j.juro.2014.08.082
Rigatti, 2011, Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography, Eur Urol, 60, 935, 10.1016/j.eururo.2011.07.060
Studer, 2008, Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891), Eur Urol, 53, 941, 10.1016/j.eururo.2007.12.032
van den Bergh, 2016, Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review, Eur Urol, 69, 802, 10.1016/j.eururo.2015.11.023
Bayoumi, 2000, Cost-effectiveness of androgen suppression therapies in advanced prostate cancer, J Natl Cancer Inst, 92, 1731, 10.1093/jnci/92.21.1731
Nair, 2002, Early versus deferred androgen suppression in the treatment of advanced prostatic cancer, Cochrane Database Syst Rev, CD003506
Oefelein, 2000, Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making, Urology, 56, 1021, 10.1016/S0090-4295(00)00793-7
Morote, 2009, Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy, BJU Int, 103, 332, 10.1111/j.1464-410X.2008.08062.x
Pickles, 2012, Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?, BJU Int, 110, E500, 10.1111/j.1464-410X.2012.11190.x
Seidenfeld, 2000, Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis, Ann Intern Med, 132, 566, 10.7326/0003-4819-132-7-200004040-00009
Crawford, 2014, Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix, Urology, 83, 1122, 10.1016/j.urology.2014.01.013
Tsushima, 2001, Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist, Urol Int, 66, 135, 10.1159/000056592
Iversen, 2002, Antiandrogen monotherapy: indications and results, Urology, 60, 64, 10.1016/S0090-4295(02)01576-5
Smith, 2004, Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition, J Clin Oncol, 22, 2546, 10.1200/JCO.2004.01.174
Kunath, 2014, Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer, Cochrane Database Syst Rev, 6, CD009266
2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2
Schmitt, 2000, Maximal androgen blockade for advanced prostate cancer, Cochrane Database Syst Rev, CD001526
Akaza, 2009, Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival, Cancer, 115, 3437, 10.1002/cncr.24395
Niraula, 2013, Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials, J Clin Oncol, 31, 2029, 10.1200/JCO.2012.46.5492
Sciarra, 2014, A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy?, Eur Urol, 65, 905, 10.1016/j.eururo.2013.06.034
Botrel, 2014, Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis, BMC Urol, 14, 9, 10.1186/1471-2490-14-9
Brungs, 2014, Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis, Prostate Cancer Prostatic Dis, 17, 105, 10.1038/pcan.2014.10
Hussain, 2013, Intermittent versus continuous androgen deprivation in prostate cancer, N Engl J Med, 368, 1314, 10.1056/NEJMoa1212299
Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 149, 10.1016/S1470-2045(12)70560-0
Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005
Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747
James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5
Smith, 2015, Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 33, 3199, 10.1200/JCO.2015.62.3488
Collette, 2003, Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892), Eur Urol, 44, 182, 10.1016/S0302-2838(03)00251-3
Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487
Smith, 2006, Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer, J Urol, 175, 136, 10.1016/S0022-5347(05)00033-9
Saylor, 2009, Metabolic complications of androgen deprivation therapy for prostate cancer, J Urol, 181, 1998, 10.1016/j.juro.2009.01.047
Faris, 2010, Metabolic sequelae associated with androgen deprivation therapy for prostate cancer, Curr Opin Endocrinol Diabetes Obes, 17, 240, 10.1097/MED.0b013e3283391fd1
Smith, 2005, Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, J Clin Oncol, 23, 2918, 10.1200/JCO.2005.01.529
Smith, 2011, Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer, Cancer., 117, 2077, 10.1002/cncr.25762
Crawford, 2014, Challenges and recommendations for early identification of metastatic disease in prostate cancer, Urology, 83, 664, 10.1016/j.urology.2013.10.026
Hussain, 1994, Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report, J Clin Oncol, 12, 1868, 10.1200/JCO.1994.12.9.1868
Taylor, 1993, Importance of continued testicular suppression in hormone-refractory prostate cancer, J Clin Oncol, 11, 2167, 10.1200/JCO.1993.11.11.2167
Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096
Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7
Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095
Kantoff, 2010, Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer, J Clin Oncol, 28, 1099, 10.1200/JCO.2009.25.0597
Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720
Eisenberger, 2007, A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC), J Clin Oncol, 25
Armstrong, 2010, Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer, Clin Cancer Res, 16, 203, 10.1158/1078-0432.CCR-09-2514
Horgan, 2014, Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial, J Geriatr Oncol, 5, 119, 10.1016/j.jgo.2013.12.001
Kellokumpu-Lehtinen, 2013, 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial, Lancet Oncol, 14, 117, 10.1016/S1470-2045(12)70537-5
Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755
Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257
Pezaro, 2014, Visceral disease in castration-resistant prostate cancer, Eur Urol, 65, 270, 10.1016/j.eururo.2013.10.055
Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815
Beer, 2004, Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer, Br J Cancer, 91, 1425, 10.1038/sj.bjc.6602198
Ohlmann, 2006, Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy, Eur Urol Suppl, 5, 10.1016/S1569-9056(06)60295-9
de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X
Resnick, 2015, Prostate cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement, J Clin Oncol, 33, 1078, 10.1200/JCO.2014.60.2557
de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618
Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0
Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506
Dy, 2008, Evidence-based standards for cancer pain management, J Clin Oncol, 26, 3879, 10.1200/JCO.2007.15.9517
Hartsell, 2005, Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases, J Natl Cancer Inst, 97, 798, 10.1093/jnci/dji139
Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458
Aapro, 2008, Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel, Ann Oncol, 19, 420, 10.1093/annonc/mdm442
Smith, 2012, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, Lancet, 379, 39, 10.1016/S0140-6736(11)61226-9
Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6
Esper, 1997, Supportive care in the patient with hormone refractory prostate cancer, Semin Urol Oncol, 15, 56